Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT05545150

PHASE2

Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study

Sponsor: Northwestern University

View on ClinicalTrials.gov

Summary

This clinical trial assesses if the use of a three-dimensional imaging device called the Clarix Imaging Volumetric Specimen Imager (VSI) can help guide and assist surgeons in identifying and removing all positive margins while in the operating room (intraoperative imaging) for patients with breast cancer and breast ductal carcinoma in situ. Breast conservation surgery or lumpectomy is a standard of care (routine) procedure that removes the tumor and a rim of surrounding normal tissue (margins) while leaving as much normal breast tissue as possible. A margin that does not contain tumor cells is called a negative margin and tells the surgeon that the primary tumor has been removed. A positive margin contains tumor cells at or near the edge of the tissue removed. As part of standard of care, surgeons take two-dimensional x-ray images of the tissue that has been removed in the operating room to assess if there is any additional tissue that should be shaved (removed) to get a negative margin. After the surgery is over, the tissue is examined once again by a pathologist in a laboratory to determine if there are any small pieces of tumor left in the margin that were not visible during surgery. If residual tumor is detected in the margin, a reoperation may be required to remove additional tissue until the tumor has been completely removed from the margin. Diagnostic procedures, such as intraoperative volumetric specimen imaging may reduce the rate of reoperation of for patients who previously underwent lumpectomy.

Official title: Volumetric Lumpectomy Specimen Image Visualization for Intraoperatively Directing Cavity Shaves, a Phase II Study (VIVID)

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

113

Start Date

2022-11-28

Completion Date

2026-07-01

Last Updated

2025-02-07

Healthy Volunteers

Conditions

Anatomic Stage 0 Breast Cancer AJCC v8 Bilateral Breast Carcinoma Breast Ductal Carcinoma In Situ Invasive Breast Carcinoma Multicentric Breast Carcinoma Prognostic Stage 0 Breast Cancer AJCC v8

Interventions

PROCEDURE

Intraoperative Imaging

Clarix Imaging Volumetric Specimen Imager

DEVICE

Lumpectomy

Per standard of care (SOC)

Inclusion Criteria: * Women with invasive breast cancer and/or ductal carcinoma in situ (DCIS) who will be undergoing breast conservation surgery, consisting of a lumpectomy or partial mastectomy procedure * Patients must be planning and able to undergo breast conservation surgery with planned localization (any localization device is eligible) and intraoperative imaging for the management of invasive breast cancer and/or DCIS. * Patients must have histologically confirmed invasive breast cancer, ductal carcinoma in situ (DCIS), or invasive breast cancer with a DCIS component. * The invasive breast cancer and/or DCIS lesion must have been visualized on mammography/ digital breast tomosynthesis (DBT), ultrasound (US), or magnetic resonance imaging (MRI). * Note: Patients with mammographically occult lesions are eligible, provided the lesion can be visualized using MRI or US. * Patients must be women who are \>= 18 years of age. * NOTE: Males and children under the age of 18 are not included in this study because the treatment paradigms for these groups are aggressive and routinely include mastectomy, whereas the present study is an investigation of breast conservation. * The patient (or the patient's legally authorized representative if the patient has impaired decision-making capacity) must have the ability to understand and provide voluntary written informed consent to participate in this study, prior to registration. * Patients who have received neoadjuvant chemotherapy for the treatment of breast cancer are eligible * Patients with bilateral breast cancer and/or multicentric disease are eligible. * Note: For these patients, the VSI device will only be used on a single lesion * Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational intervention for this trial are eligible. Exclusion Criteria: * Patients undergoing re-excision for invasive breast cancer or DCIS are not eligible * Patients who are expected to have an excised lumpectomy specimen that is larger than 9 cm x 9 cm x 7 cm are not eligible * Note: The specimen size limitation for the VSI device is 9 cm x 9 cm x 7 cm (length x width x height). * Patients must not have a physical or psychiatric illness, condition, or social circumstance that the investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints.

Locations (4)

Northwestern University

Chicago, Illinois, United States

The University of Kentucky

Lexington, Kentucky, United States

Washington University in St. Louis

St Louis, Missouri, United States

Cleveland Clinic

Cleveland, Ohio, United States